Pelacarsen Trial Fails
Novartis Phase 3 Pelacarsen Trial Fails to Reduce Major Cardiovascular Events
Anonymous
Key Points
1
Lp(a)HORIZON was described as the first pivotal Phase 3 trial designed to test whether lowering the genetically influenced risk factor Lp(a) would reduce cardiovascular events, rather than merely improve a laboratory measurement.
2
Ionis Pharmaceuticals discovered pelacarsen and conducted its early development before licensing the drug to Novartis in 2019; the company said the results would inform future cardiovascular care as it continues developing other RNA-based medicines.
3
Novartis’ topline announcement did not provide numerical event rates, hazard ratios or statistical values, leaving the magnitude and statistical detail of the trial outcome for the full presentation at a future medical congress.
4
Analysts had estimated that pelacarsen, remibrutinib and a once-yearly follow-on to inclisiran together could generate more than $10 billion in peak sales, helping offset expected patent cliffs for Cosentyx and Kisqali later this decade; one bank argued that Novartis’ roughly 16-times forward-earnings valuation was particularly vulnerable if at least two of the three programs failed.
Novartis' experimental heart drug pelacarsen failed to prevent heart attacks and strokes in a pivotal late-stage trial, marking a major setback for a new approach to cardiovascular disease. The Phase 3 Lp(a)HORIZON trial involved more than 8,000 patients with elevated lipoprotein(a) and existing heart disease. Although pelacarsen substantially lowered Lp(a) levels and was safe, those improvements did not translate into fewer cardiovascular deaths, heart attacks, strokes, or emergency procedures, according to Clinical Trial Vanguard.
The failure threatens Novartis' growth plans. Wall Street had expected pelacarsen, along with two other drugs, to generate over $10 billion in peak sales and offset patent cliffs coming later this decade. NDTV Profit reported that the trial result represents a significant pivot point for the cardiometabolic field, as Lp(a)-targeted therapies face renewed questions about their clinical value.
Why Lp(a) Matters in Heart Disease
Lipoprotein(a) is a genetically determined blood particle that raises heart attack and stroke risk. Unlike cholesterol, Lp(a) levels are largely fixed by genetics, making it an attractive target for drug makers. Lp(a)HORIZON was the first Phase 3 trial designed to prove that lowering this specific risk factor would reduce actual cardiovascular events, not just improve lab numbers, according to IJR.
A Major Blow to Novartis' Pipeline Strategy
Novartis licensed pelacarsen from Ionis Pharmaceuticals in 2019, betting it would become a cornerstone product for preventing heart disease in patients already on standard treatments. Analysts estimated the drug could hit blockbuster status. Instead, NDTV Profit noted, the failure creates real pressure on Novartis' valuation, especially since investors viewed pelacarsen as critical to offsetting future patent expirations of key medicines like Cosentyx and Kisqali.
Royalty Pharma Protected From Financial Fallout
Royalty Pharma had structured its earlier funding agreement with Ionis to limit exposure to pelacarsen's risk. The deal allowed Royalty Pharma to recoup its investment primarily through royalties from Spinraza, an existing profitable drug. Market Screener reported that Royalty Pharma avoided expected milestone payments tied to pelacarsen's approval, shielding it from the trial's negative impact.
What Comes Next for Lp(a) Research
Novartis and Ionis said the trial findings will inform future cardiovascular care and the development of other RNA-based medicines. Archynetys reported that cardiologists are now questioning whether targeting Lp(a) alone is sufficient. Full data from the trial will be presented at a future medical conference. The setback raises questions about whether other experimental Lp(a) drugs in development will face similar obstacles.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
107
Reach
126
A
AnonymousAuthor
